Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Vertex Pharmaceuticals Trading Up 0.4 %
NASDAQ:VRTX opened at $504.77 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The business has a 50 day simple moving average of $457.74 and a 200 day simple moving average of $462.02. The firm has a market capitalization of $129.62 billion, a P/E ratio of -229.44, a P/E/G ratio of 2.11 and a beta of 0.41.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on Vertex Pharmaceuticals
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Capital World Investors boosted its position in Vertex Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company’s stock worth $11,406,667,000 after acquiring an additional 1,514,993 shares during the period. Vanguard Group Inc. boosted its position in Vertex Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company’s stock worth $9,366,113,000 after acquiring an additional 98,654 shares during the period. State Street Corp lifted its holdings in shares of Vertex Pharmaceuticals by 0.8% in the third quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock valued at $5,495,501,000 after buying an additional 90,173 shares during the period. Capital Research Global Investors lifted its holdings in shares of Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company’s stock valued at $4,199,713,000 after buying an additional 1,426,746 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company’s stock valued at $2,382,407,000 after buying an additional 1,117,214 shares during the period. Institutional investors and hedge funds own 90.96% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Why Invest in High-Yield Dividend Stocks?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Calculate Inflation Rate
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Best Aerospace Stocks Investing
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.